SCHEDULE: StemPoint Capital Reports 5% Stake in Surrozen

StemPoint Capital LP, along with affiliated entities, has reported beneficial ownership of 5.0% of Surrozen, Inc.'s common stock, primarily through warrant holdings.

Summary

• StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross (collectively, the 'Reporting Persons') have jointly filed a Schedule 13G.
• The filing indicates beneficial ownership of 602,798 shares of Surrozen, Inc. common stock, representing 5.0% of the class.
• This ownership includes 273,140 directly held shares and 329,658 shares underlying Series A, Series B, and Series E Warrants.
• The Reporting Persons have shared voting power over 543,495 shares and shared dispositive power over 602,798 shares.
• The Series A, B, and E Warrants are subject to a 9.99% beneficial ownership limitation.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not dominant ownership stake. The focus is on reporting existing holdings and warrant exercises, rather than new strategic initiatives.

Positives

• Reporting Persons have acquired a significant stake, reaching the 5.0% ownership threshold.
• The ownership is diversified across direct shares and exercisable warrants, providing potential for increased stake.
• The joint filing agreement clarifies responsibilities among the reporting entities.

Negatives

• The beneficial ownership of warrants is capped at 9.99%, limiting immediate control or influence through warrant exercise.
• The filing does not indicate any new strategic investment or change in control intentions.

Risks

• The 9.99% beneficial ownership limitation on warrants could restrict the Reporting Persons' ability to increase their stake beyond this threshold without further action or waivers.
• Fluctuations in Surrozen, Inc.'s stock price could impact the value of the warrants and the overall investment.

Future Outlook

The filing does not contain forward-looking statements or specific future guidance. It primarily reports on current beneficial ownership and the potential exercise of existing warrants.

Management Comments

• Each Reporting Person shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes. Surrozen, Inc. operates in the biotechnology sector, where significant ownership by investment firms can precede various strategic developments.

Stakeholder Impact

• Shareholders: The increased reporting of a significant stake by an investment firm may influence market perception and trading activity.
• Management: The 5.0% stake indicates a notable institutional investor presence, which could lead to increased engagement on corporate strategy.

Next Steps

• The Reporting Persons will continue to monitor their beneficial ownership and file amendments to the Schedule 13G as required by SEC regulations.
• Potential exercise of Series A, B, and E Warrants, subject to the 9.99% beneficial ownership limitation.

Key Dates

Keywords

Surrozen, StemPoint Capital, Schedule 13G, Beneficial Ownership, Warrants, Investment, Common Stock